| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.18 | 0.0004 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |